Insurance can be a **PAIN**.

Your patients' knees don't have to be.



an ideal option for self-pay patients.

Do not let changes in insurance coverage, change how you treat your patients!

Hyaluronic acid (HA) injections provide meaningful relief of knee pain and stiffness due to mild to moderate knee osteoarthritis (OA) patients.¹

HA Injections:

- · Provide up to 6 months of knee pain relief
- Have no risk of renal or other systemic complications as compared to NSAIDs or IA corticosteroid injections²
- Reduce the use of NSAIDS, steroids and opioids³
- Are safe for repeated usage
 - Repeated steroid injections can lead to cartilage damage and loss⁴
- May delay need for total knee replacement (TKR) surgery up to 3.6 years⁵

HA Injections Associated with Delay in TKR Surgery⁵



Many knee OA patients need additional therapy beyond first-line oral treatments

Give patients options for continuing trusted therapy.

If insurance coverage becomes a challenge for treating knee OA patients

Turn to SUPARTZ FX

- Proven OA knee pain relief for up to six months⁶
- · Approved for 3 to 5 injections, providing flexible dosing options


Low average sales price per syringe⁷

Product	Average Sales Price (ASP)*
SUPARTZ FX	\$83.18
GENVISC-850®	\$156.30
SYNVISC®	\$187.18
EUFLEXXA®	\$143.72
ORTHOVISC®	\$140.34

*Based on Average Sales Price (ASP) for selected HA products that report an ASP to CMS, as of Q3 2018 ASP.

Direct pricing to physicians may vary.

Talk with your local representative about SUPARTZ FX as a self-pay option for knee OA patients.





Effective, Safe, Affordable



Talk with your local representative about SUPARTZ FX as an option for your self-pay patients with knee OA.

References: 1. Bhandari M, Bannuru R, et al. Intra-articular hyaluronic acid in the treatment of knee osteoarthmitis: a Canadian evidence-based perspective. *Ther Adv in Musculoskel Dis*. 2017;9:231-2446. 2. Bannuru RR, Natov NS, Obadan IE, Price LL, Schmid CH, McAlindon TE, Therapeutic trajectory of hyaluronic acid versus corticosteroids in the treatment of knee osteoarthmitis: a systematic review and meta-analysis. *Arthntis Rheum*. 2009;61(12):1704-11. 3. McIntyre L, Beach W, et al. Impact of Hyaluronic acid injections on Utilization of Pain Management Medications. *Am J Pharm Benefits*. 2017;9(6):195-199 4. McAlindon TE, LaValley MP, Harvey WF, et al. Effect of Intra-articular triamcinolone vs saline on knee cartilage volume and pain in patients with knee osteoarthritis: a randomized clinical trial. *JAMA*. 2017;317(19):1967-75. 5. Altman R, Lim S, Steen RG, Dasa V, Hyaluronic acid injections are associated with delay of total knee replacement surgery in patients with knee osteoarthritis: vidence from a large US. health claims database. *PLoS ONE*. 2015;10(12):e0145776. doi: 10.1371/journal.pone.01457766. SUPARTZ FX [Package Insert]. Durham, NC: Bioventus LLC; 2015 7. Centers for Medicare & Medicaid Services. 2018 ASP drug pricing files. www.cms.gov/Medicare/Medicare-Fee-for-Service-Part-B-Drugs/McPartBDrugAvgSalesPrice/2018ASPFlies.html.

Summary of Indication for Use: SUPARTZ FX is indicated for treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative non-pharmacologic therapy and simple analgesics, e.g., acetaminophen.

You should not use SUPARTZ FX if you have infections or skin diseases at the injection site or allergies to poultry products. SUPARTZ FX is not approved for pregnant or nursing women, or children. Risks can include general knee pain, warmth and redness or pain at the injection site. Full prescribing information can be found in product labeling, at www.SupartZFX.com or by contacting Customer Service at 1:400-836-4080.

All trademarks acknowledged and are respective properties of their owners Bioventus and the Bioventus logo are registered trademarks of Bioventus LLC. SUPARTZ FX is a registered trademark of Seikagaku Corp. ©2018 Bioventus LLC. All rights reserved. SMK-002617 06/18

